STUTTGART, Germany I July 30, 2025 I La Merie Publishing released its newest product entitled: Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis.

CONSHOHOCKEN, PA, USA I July 30, 2025 I Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive ...

PARIS, France I July 30, 2025 I The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent ...

Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of ...

REDWOOD CITY, CA, USA & SHENZHEN, China I July 29, 2025 I LTZ Therapeutics (“LTZ”), an immunotherapy-focused biotechnology company, today announced a ...

LAVAL, Canada and CUPERTINO, CA, USA I July 29, 2025 I Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and ...

ETB, is expected to enroll over 500 patients with a primary endpoint of proportion of patients demonstrating functional independence at 90 days and is being conducted under a Special Protocol ...

The anti-CD226 mAb adds to Formation Bio’s growing pipeline which currently includes programs in immunology, dermatology, and rheumatology and reflects the company’s focus on first- and best-in-class ...

Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs of ...

US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos Purchase price is $55m in cash to be paid upon consummation of the sale with up ...

Indication SEPHIENCE is indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE ...

PARIS, France I July 28, 2025 I Genethon, a worldwide pioneer and leader in research and development in gene therapy for rare genetic diseases, has received ...